+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Treatment of HER2 overexpressing metastatic breast cancer with trastuzumab and chemotherapy



Treatment of HER2 overexpressing metastatic breast cancer with trastuzumab and chemotherapy



Breast Cancer Research & Treatment 64(1): 123




(PDF emailed within 1 workday: $29.90)

Accession: 035980451

Download citation: RISBibTeXText


Related references

Magnitude of HER2 amplification as a predictive factor for HER2-overexpressing metastatic breast cancer treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy. Journal of Clinical Oncology 26(15_suppl): 1053-1053, 2016

A novel Bayesian dose-escalation phase Ib design investigating safety of combination of RAD001 with chemotherapy plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Journal of Clinical Oncology 26(15_suppl): 1130-1130, 2016

Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. International Journal of Clinical Oncology 14(1): 48-52, 2009

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62(1): 209-243, 2002

Predictive value of activated tyrosine kinase in patients with HER2-overexpressing metastatic breast cancer treated with trastuzumab + chemotherapy regimens. EJC Supplements 2(3): 173-174, 2004

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet. Oncology 17(3): 357-366, 2016

Predictive value of activated tyrosine kinase (Tyr1248) in patients with HER2-overexpressing metastatic breast cancer (MBC) treated with trastuzumab + chemotherapy regimens. European Journal of Cancer Supplements 2(3): 173-174, 2004

Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer. Clinical Breast Cancer 9(3): 178-183, 2009

Trastuzumab plus GM-CSF for patients with trastuzumab-resistant, HER2-overexpressing metastatic breast cancer: Pilot study. Journal of Clinical Oncology 23(16_suppl): 803-803, 2016

Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. Breast Care 9(5): 344-348, 2015

Oral and intravenous vinorelbine plus trastuzumab for 1st-line treatment of HER2-overexpressing metastatic breast cancer (MBC). A trial of the german AIO breast cancer group. Journal of Clinical Oncology 26(15_suppl): 1061-1061, 2016

Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 26(15_suppl): 1138-1138, 2016

Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer. Drugs 69(15): 2125-2148, 2010

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110(5): 965-972, 2007

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 20(3): 719-726, 2002